Sarikun Tjandra, MD
Pulmonary Disease · Fort Smith, ARNPI 1891704227
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,462 and has fallen 97.6% since, to $59 in 2025. That places this record below the midpoint for pulmonary disease clinicians in AR, where the typical reported total is $3,332.
Across 195 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$598
- Boehringer Ingelheim$361
- Grifols USA, LLC$355
- AstraZeneca$292
- Genentech USA, Inc.$287
- Actelion Pharmaceuticals US, Inc.$230
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,26898%
- Education$532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 39 | $598 |
| Boehringer Ingelheim | 28 | $361 |
| Grifols USA, LLC | 15 | $355 |
| AstraZeneca | 17 | $292 |
| Genentech USA, Inc. | 15 | $287 |
| Actelion Pharmaceuticals US, Inc. | 11 | $230 |
| Johnson & Johnson | 7 | $155 |
| AbbVie(2 entities) | 7 | $127 |
| Mallinckrodt Enterprises LLC | 5 | $103 |
| Novo Nordisk | 5 | $89 |
| Sunovion Pharmaceuticals Inc. | 9 | $88 |
| Lilly USA, LLC | 5 | $72 |
| Merck | 4 | $72 |
| Pfizer | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Circassia Inc. | 3 | $41 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Melinta Therapeutics, LLC | 1 | $33 |
| Exact Sciences | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Mylan Specialty L.p. | 1 | $22 |
| Shire North American Group Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Electromed, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Novartis | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Bayer | 1 | $13 |
| Amgen | 1 | $13 |
| United Therapeutics Corporation | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C$125
- TRELEGY ELLIPTA$123
How this compares
$3,320 in reported general payments places this provider in the 45th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $60,697 |
| FarxigaDapagliflozin Propanediol | 61 | $49,854 |
| JardianceEmpagliflozin | 27 | $35,267 |
| TrulicityDulaglutide | 25 | $26,485 |
| EntrestoSacubitril/Valsartan | 21 | $17,620 |
| XareltoRivaroxaban | 11 | $8,162 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $3,791 |
| Omega-3 Acid Ethyl Esters | 11 | $2,143 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 12 | $2,058 |
| Atorvastatin Calcium | 230 | $1,401 |
| Triamcinolone Acetonide | 31 | $1,110 |
| Gabapentin | 50 | $1,058 |
| Potassium Chloride | 28 | $781 |
| Ventolin HfaAlbuterol Sulfate | 14 | $772 |
| Azelastine Hcl | 32 | $743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $89 | $60,69762 claims |
| AstraZenecaFarxiga | $292 | $49,85461 claims |
| Boehringer IngelheimJardiance | $361 | $35,26727 claims |
| Lilly USA, LLCTrulicity | $72 | $26,48525 claims |
| NovartisEntresto | $15 | $17,62021 claims |
| Johnson & JohnsonXarelto | $155 | $8,16211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Fort Smith
- Arturo MeadeFort Smith$67K
- Daphne MacbruceFort Smith$10K
- Adebayo FasanyaFort Smith$8K
- Muhammad MirFort Smith$4K
- Francisco TamayoFort Smith$3K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.